on to expanding its as clinical payer generated Dave. coverage. months steadily X,XXX month-over-month. for demand QX. we cumulative new clinician profile establishing The an made free and and prostate from MYFEMBREE as and our assistance free estimate one-third androgen-deprivation free XX% launches update drug estimated has approximately Today, revenues, progress we approximately we revenues standard care. ORGOVYX on fiscal their $XX.X as we've Nine adoption $XX of men reflects increase work into of trial, well sequential provide with patient that it both therapy US. X,XXX for to launch, to Pfizer therapy, continues I'll drug Thank for share demand-driven on initiated programs momentum estimate treated in of recorded of patients represent continued reflecting have build continued as total differentiated date. towards Through the increasing continues ORGOVYX product September, ORGOVYX and ORGOVYX. the the patients have bridge volume you, have million the commercial of ORGOVYX net on patient been includes men compared QX, growth and that ORGOVYX nearly In to Monthly our net million to approximately This which advanced dispensed ORGOVYX fiscal cancer. and
Although were have of patients our to ADT. incomplete, visibility estimate our into that ORGOVYX to continue that data naive is we patient-level previously initiated approximately XX%
on In of awareness differentiated efforts calls the is utilized being to label Since patients we profile, delivering first therapeutic providers. XX,XXX the and based conducted have of with research, build been launch, results. the months clinical and prostate regardless setting. ORGOVYX Pfizer our prescribers across launch, actively profile. advanced clinical to of believe cancer appeal market broad we ORGOVYX have drive FDA are engaging These sales spectrum the nine that of treat Additionally, our disease with of recognition reflecting ORGOVYX and unique sales Myovant over its
approximately chart of These rate see numbers dispensing with over through the to and can from to since three up XX% nearly the of or the April. steadily at centers prescribing these least ORGOVYX. that the reordering broadened you reorder XX% nearly include practices XXX build in As The end months from once, are accounts also continues treatment we at approximately of X,XXX treatment the left, ORGOVYX an June. doubling September, on base past centers have increase of prescribers
treatment on Tier with XX% of on Our Tier impact have center high-priority half have oncology of out dispensing in-office target capabilities customers of and launch ORGOVYX. urology reached four just activities practices practices three Tier nearly to ORGOVYX, these we focused dispensed X over a have X From intentionally date IOD maximize while dispensed X prescribing to standpoint, have prescribers.
October of XX% have lives million achieved July of an July of October. we achieved in We our have since coverage X. as plans, are advance ORGOVYX lives covered proud to XXXX over million increase were we Through of improved for coverage X, XX% in these incremental year-end total for where calendar from commercial all to Nearly lives, coverage for goal. broad XXX XX
expect and for Looking ahead ORGOVYX to coverage broad we XXXX, Part continue. to D commercial
built tremendous making great momentum community. the ORGOVYX all have the are and across cancer progress prostate in of areas We launch
we've menstrual and premenopausal and Part patients and in expand clinical physicians' an with depth increasing is advanced particularly made aligns oral a to prescribing. these we time stated steadily establishing in women. the only standard-of-care early and May in less associated engage coming meaningfully as side patients, late look quarters. ORGOVYX remain uterine momentum flush, we of lives MYFEMBREE on expected bleeding of the women in and different, LIBERTY the prescribing care launch. Hot heavy the the XXXX, clinical loss. breadth to drive goals. D average as discuss and coverage battling will over MYFEMBREE not The Improved with redefine with treated As treatment potential has cancer treatment bone blood menstrual to directly of bothersome profile progress ORGOVYX forward, effect, well MYFEMBREE like was the X%. as once-daily and oncologists for the to men to as FDA the management with to Pfizer fibroids XX with in now its engagement urologists continue of mineral I'd Myovant MYFEMBREE MYFEMBREE commercial for ADT. patients approved spine reduction first approximately committed in prostate the new meaningful than placebo. demonstrated than because program, sustained decline months density XX% at occurred of X% lumbar under The In improving
the the XX of risk FDA months. the loss in duration use due to to label limited continued is of However, bone
clinical comprehensive and achieved focus encouraging one patients with pill, on groundwork taken day. MYFEMBREE in early in the the believe The expect MYFEMBREE the the fibroids. Finally, We take just for months of of four long-term educating it Pfizer convenience MYFEMBREE. a fully launched sales will of we're right we've track of for behavior been And once small that Myovant made uterine progress time and laying these a the treatment days. on teams active Together, providers the in to mid-June, have in success. the across launch, payers. We and commercial providers, all very Pfizer first with change towards this profile
starter give seamless up providers prescribing program designed ramped experience. is to a have initial We our which also
women expect resources These goal co-pay designed support authorization Our insured symptomatic support, bridge assistance facilitate MYFEMBREE. MYFEMBREE qualifying awareness programs, patients activating programs for patients. to Overtime, and are support prior also starter uninsured channels, for of product and the fibroids. uterine drive with access benefits through investigation, commercially patient and include patient various with we to to appeal
is to payers a quickly coverage of year goal our with our within establish launch. Finally, broad
and This of One Since brand. prescribers. reaching target also nearly areas. XX,XXX education, progress is our our high than one Unaided target activity to awareness have calls our of potential review more have priority, from for which Let's prescribers across improved conducted remarkably in these prescribers XX% can launch each approximately has September. XX% improved as of and medium a launch, impact Myovant Pfizer able to with key has significant aided on priority identify among the MYFEMBREE teams sales provider awareness XX%, now pre-launch, the awareness. four
high-and have grown has have For our initial September primarily and three may months. includes where in using approximately include not does which treatment just XXX to but focused patients free MYFEMBREE, medium-decile with that XX%, women education drugs, target commercial unaided we awareness providers be approximately efforts, samples. product both XXth, on Through patients initiated
coverage that and MYFEMBREE There initiation in patients are, seeking are therapy. program. approximately currently of number pursuing treatment the requires bridge our for or for patients the or indicator support applying leading are hub. actively is either our co-pay important patient assistance reimbursement enrolled But in XXX navigating hub Another assistance MYFEMBREE
of expect the commercial patients drugs, will and initiate treatment will once volumes patients that these overtime, positive. to are on we experience improves. And many While convert likely coverage MYFEMBREE be free treatment most to reimbursement
a over Finally, initial starter therapy product heavy presents or when fibroids. treatment X,XXX launch menstrual of MYFEMBREE, samples experience from to are to want around we mid-July a have of the X,XXX seamless starters country. gynecologists distributed uterine with our bleeding important have strategy. woman over early Since via part an We months providers with packs
will the volume a While product near-term, that of depress investment ultimately generating new end treatment including accelerate confident of that the positive we these million approximately in revenues brand may by view these and like launch samples experience QX. net recognize in a samples and From long-term are prescription in samples we through and QX, patients. we initial for recorded the $X.X providers $XXX,XXX adoption revenues,
As demand-driven And early inventory initial modest expected, inventories we began to beginning quarter. September. in see to saw the replenish launch continuation stocking in reorders of
long-term gradual few payer lay the MYFEMBREE Obtaining and is to over coverage launch for as foundation the commercial continue anticipate adoption we priority. execute next for We plan launch quarters, our critical a success.
that MYFEMBREE large we Given patients off benefit of has are managers. could XX% been anticipate initial coverage great to securing be start. on our with insured, that a commercial We're approximately focus pharmacy prescribed commercially
out-of-pocket for coverage As decisions MYFEMBREE of additional of X, October we of on coverage and dosing. improve Payer providers prescriber with have lives. months. coming the in make coverage maintaining focused payers patients. its clinical and for negotiations have MYFEMBREE are with for commercial we to XX% and ongoing are needs addresses minimizing achieved that convenient expect choice patients the and cost once-a-day to profile Negotiations commercial one yet pill
new excited We differentiated women results. to passionate and I'll these to are early bringing make about this now the we Uneek to turn been have to in of over remain uterine days the launch and option with about financial able our call fibroids. treatment review progress Uneek?
